Login to Your Account



NewCo News

Helmedix Lands Seed Funding to Back Helminth Peptide R&D

By Nuala Moran
Staff Writer

Wednesday, March 20, 2013
Start-up Helmedix Pty Ltd. has raised A$1.25 million (US$1.29 million) in seed funding, providing a springboard to the commercialization of molecules based on immune-modulating peptides used by helminth parasites to suppress the immune response of their hosts.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription